FBRX - NASDAQ
Forte Biosciences, Inc.
$16.69
-8.2%Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
At a Glance
Live Snapshotfbrx
Cash at Beginning of Period
Last Annual Value
22.24M
3-Year CAGR
-19%
5-Year CAGR
26%
10-Year CAGR
18%
Forte Biosciences, Inc. Competitors Analysis of Cash at Beginning of Period
| Company | Cash at Beginning of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Forte Biosciences, Inc. NASDAQ:FBRX | 22.24M | -18.5% | -17.7% | 10.6% | |
 Nkarta, Inc. NASDAQ:NKTX | 30.62M | -8.7% | -20.6% | N/A | |
 Cardiff Oncology, Inc. NASDAQ:CRDF | 51.47M | 46.6% | -17.0% | -2.7% | |
 Seres Therapeutics, Inc. NASDAQ:MCRB | 39.46M | -38.7% | -19.4% | -6.1% | |
 Tonix Pharmaceuticals Holding Corp. NASDAQ:TNXP | 99.68M | -6.1% | 5.2% | 17.9% | |
 Actuate Therapeutics Inc NASDAQ:ACTU | 8.64M | -25.0% | N/A | N/A | |
 Applied Therapeutics, Inc. NASDAQ:APLT | 49.90M | 44.2% | -2.8% | N/A | |
 Fate Therapeutics, Inc. NASDAQ:FATE | 46.28M | -9.0% | -24.0% | -3.3% | |
 PepGen Inc. NASDAQ:PEPG | 50.97M | -34.7% | 39.1% | N/A | |
 Alector, Inc. NASDAQ:ALEC | 34.87M | -39.3% | -7.5% | -6.2% | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 17.87M | 1.3% | -27.0% | 3.7% |
Forte Biosciences, Inc. Fair Value Envelope
Related Guides
Continue your FBRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.